Noxopharm Eyeing to Revolutionise Cancer Therapy; Focusing on Turning Veyonda® into Reality

Australia headquartered clinical stage drug development company, Noxopharm Limited (ASX: NOX) has been in the spotlight for its potentially transformative therapy in late-stage prostate cancer where few or no standard therapy exists currently.

Noxopharm recently released a corporate presentation to its shareholders and the market, providing a general outlook with an update on its clinical strategy as well as commercialisation and funding strategies.

Veyonda® – first-in-class S1P inhibitor

Noxopharm believes that its lead drug candidate Veyonda® (NOX66) has the potential to become a commonly used anti-cancer drug within a few years.

A novel patented formulation of idronoxil, Veyonda® is a first-in-class, sphingosine-1-phosphate inhibitor (S1P) that reinstates the ability of the body’s immune system to fight and eliminate cancer.

The inhibitory effect of Veyonda® is on an oncogene upstream of S1P which makes it unique from any other S1P inhibitor. Another distinctive feature of Veyonda® is that it only blocks S1P in cancer cells and some high-turnover cells.

Bringing Veyonda® to Market

During its journey so far, Noxopharm remained engaged in determining the most assured path to market for Veyonda®, with three potential methods of use including, monotherapy, combination therapy and immunotherapy in the first three years.

The company selected DARRT based on following considerations-

  • Encouraging positive clinical outcomes in DARRT-1;
  • Absence of disease progression at 6-months in more than 50% of men, indicating its potential to possibly achieve OS (Overall Survival) outcome;
  • No noteworthy safety issues;
  • Ability to cater to large unmet need;
  • Guidance received from Noxopharm’s U.S. Prostate Cancer Med Advisory board;
  • Prospects to apply for FDA expedited review;
  • Opportunity for Phase 2 adaptive design;
  • Only one competitive technology known till now (PSMA + radionuclide).

With the promising data of DARRT-1 study, Noxopharm is planning for DARRT-2 multi-national study next year across Australasia, North America, and Europe.

Noxopharm’s Clinical Development Program at a Glance 

Source: NOX Investor Presentation 

Both DARRT and LuPIN (Lu-PSMA in conjunction with Veyonda®) trials to date have been well-tolerated and have shown promising results in terms of tumour response, PSA, RECIST criteria and pain reduction.

A major differentiator to the standard cancer treatments is the fact that Veyonda® is very well tolerated.

Breaking down Frontiers – A future beyond Veyonda®

The convincing signal that Noxopharm is pushing the boundaries with a vision to become a major drug development and drug discovery player comes from the strategic planning of a new clinical pipeline.

The inclusion of other solid cancer types in the existing programs is expected to support Noxopharm’s intention in securing marketing approvals for Veyonda® for its successful commercialisation.

The Company is strategically planning new clinical programs including-

  • Glutamate receptor inhibitor for Glioblastoma multiforme- Noxopharm recently updated the market about the commencement of novel research program leveraging its world-leading glutamate-inhibition technology for treating glioblastoma multiforme (GBM), aiming to become first glutamate-inhibitor in the clinic for GBM, bringing a fundamental transformation in brain cancer treatment.
  • NOX66 for Nasopharyngeal cancer – Noxopharm entered into a collaboration with Hong Kong University with the aim to underpin future clinical study or strategic partnership in China. Moreover, the Company recently received a $50,000 bridging grant from Australian Academy of Technology and Science.
  • Cancer stem cell cytotoxic for various cancers
  • IRAK4 inhibitor for various cancers

Lens over Noxopharm’s Commercialisation and Funding Strategies

Noxopharm’s commercial and financial perspective was unveiled by Company’s Chief Commercial Officer, Mr. Alexander Hunter as follows –

  • Finessing commercial structure and business systems to support growth;
  • Securing necessary funding;
  • Building suitable banking and commercial US relationships;
  • Execution of clinical development plan and other commercialization pathways.

Noxopharm’s Critical Business Plan

With a goal to revolutionise cancer treatment, Noxopharm continues to develop research-oriented clinical programs and commercial opportunities in its quest of bringing to the market Veyonda® – a versatile therapy that could be a game-changer in the existing cancer treatments.

NOX last traded at $0.325 on 27 November 2019. The stock is currently placed on a trading halt (as on 28 November), pending the release of an announcement pertaining to DARRT-1 results.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is sponsored but NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) under discussion. We are neither licensed nor qualified to provide investment advice through this platform.

Checkout our Free Dividend Stocks Report

Specially made for income-hungry investors, Invest in growing Franked Dividends an opportunity that should not be missed.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report